Timeline
Coiled Therapeutics
Coiled Therapeutics doses first patient with new AO-252 formulation
Coiled Therapeutics advances softgel formulation ahead of dose expansion
Coiled Therapeutics adds two oncology specialists to Medical Advisory Board
Coiled Therapeutics appoints Professor Ozgur Sahin as Scientific Advisor
More in Biotech
Crism Therapeutics doses first patients in Phase 2 glioblastoma trial
The AIM-listed drug delivery company reported a widened first-half loss as it opened patient recruitment for its registration-grade Phase 2 trial and secured FDA orphan drug status for its lead cancer therapy.